We demonstrate that METTL3-mediated m6A modification of TERRA is essential for telomere maintenance in ALT+ NB cells and propose that inhibiting METTL3 could be a potential therapeutic option for ALT+ NB tumors. This evidence concerns the gene METTL3 and neuroblastoma.